Evidence map›Paper›PMID 30334178›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2019

Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms.

Jeffery Chakedis, Eliza W Beal, Alexandra G Lopez-Aguiar, George Poultsides, Eleftherios Makris, Flavio G Rocha, Zaheer Kanji, Sharon Weber, Alexander Fisher, Ryan Fields and 9 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 1 country.

Jeffery ChakedisDivision of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, 320 W 10th Ave, M256 Starling Loving Hall, Columbus, OH, 43210-1267, USA.
Eliza W BealDivision of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, 320 W 10th Ave, M256 Starling Loving Hall, Columbus, OH, 43210-1267, USA.
Alexandra G Lopez-AguiarDivision of Surgical Oncology, Department of Surgery, Emory University, Winship Cancer Institute, Atlanta, GA, USA.
George PoultsidesDepartment of Surgery, Stanford University, Palo Alto, CA, USA.
Eleftherios MakrisDepartment of Surgery, Stanford University, Palo Alto, CA, USA.
Flavio G RochaDepartment of Surgery, Virginia Mason Medical Center, Seattle, WA, USA.
Zaheer KanjiDepartment of Surgery, Virginia Mason Medical Center, Seattle, WA, USA.
Sharon WeberDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Alexander FisherDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Ryan FieldsDepartment of Surgery, Washington University School of Medicine, St. Louis, MI, USA.
Bradley A KrasnickDepartment of Surgery, Washington University School of Medicine, St. Louis, MI, USA.
Kamran IdreesDivision of Surgical Oncology, Department of Surgery, Vanderbilt University, Nashville, TN, USA.
Paula Marincola-SmithDivision of Surgical Oncology, Department of Surgery, Vanderbilt University, Nashville, TN, USA.
Clifford ChoDivision of Hepatopancreatobiliary and Advanced Gastrointestinal Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI, USA.
Megan BeemsDivision of Hepatopancreatobiliary and Advanced Gastrointestinal Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI, USA.
Timothy M PawlikDivision of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, 320 W 10th Ave, M256 Starling Loving Hall, Columbus, OH, 43210-1267, USA.
Shishir K MaithelDivision of Surgical Oncology, Department of Surgery, Emory University, Winship Cancer Institute, Atlanta, GA, USA.
Carl R SchmidtDivision of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, 320 W 10th Ave, M256 Starling Loving Hall, Columbus, OH, 43210-1267, USA.
Mary DillhoffDivision of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, 320 W 10th Ave, M256 Starling Loving Hall, Columbus, OH, 43210-1267, USA. Mary.Dillhoff@osumc.edu.
The Ohio State University Wexner Medical Center · USStanford University · USUniversity of Michigan–Ann Arbor · USUniversity of Wisconsin–Madison · USVanderbilt University · USVirginia Mason Medical Center · USWashington University in St. Louis · USWinship Cancer Institute

Funding

Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
NCI NIH HHS K12 CA090625
6 · The paper itself

Abstract

introductionPatients with metastatic neuroendocrine tumor (NET) often have an indolent disease course yet the outcomes for patients with metastatic NET undergoing surgery for non-hormonal (NH) symptoms of GI obstruction, bleeding, or pain is not known.

methodsWe identified patients with metastatic gastroenteropancreatic NET who underwent resection from 2000 to 2016 at 8 academic institutions who participated in the US Neuroendocrine Tumor Study Group.

resultsOf 581 patients with metastatic NET to liver (61.3%), lymph nodes (24.1%), lung (2.1%), and bone (2.5%), 332 (57.1%) presented with NH symptoms of pain (n = 223, 67.4%), GI bleeding (n = 54, 16.3%), GI obstruction (n = 49, 14.8%), and biliary obstruction (n = 22, 6.7%). Most patients were undergoing their first operation (85.4%) within 4 weeks of diagnosis. The median overall survival was 110.4 months, and operative intent predicted survival (p < 0.001) with 66.3% undergoing curative resection. Removal of all metastatic disease was associated with the longest median survival (112.5 months) compared to debulking (89.2 months), or palliative resection (50.0 months; p < 0.001). The 1-, 3-, and 12-month mortality was 3.0%, 4.5%, and 9.0%, respectively. Factors associated with 1-year mortality included palliative operations (OR 6.54, p = 0.006), foregut NET (5.62, p = 0.042), major complication (4.91, p = 0.001), and high tumor grade (11.2, p < 0.001). The conditional survival for patients who lived past 1 year was 119 months.

conclusionsPatients with metastatic NET and NH symptoms that necessitate surgery have long-term survival, and goals of care should focus on both oncologic and quality of life impact. Surgical intervention remains a critical component of multidisciplinary care of symptomatic patients.

Indexed as

AdultAgedCholestasisCytoreduction Surgical ProceduresFemaleGastrointestinal HemorrhageHepatectomyHumansIntestinal NeoplasmsIntestinal ObstructionLiver NeoplasmsMaleMiddle AgedNeoplasm GradingNeuroendocrine TumorsPainMetastaticNeuroendocrine tumorNon-hormonalPalliative surgerySymptoms

Identifiers

PMID30334178
PMCPMC10183101
OpenAlexW2896873386

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.